PLUR vs REGN · rev $1.3M vs P/E 14, rev $14.34B
Pluri Inc. (PLUR) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Pluri Inc. (PLUR) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported PLUR revenue for 2025-06-30 was $1.3M. Net income was -$23.3M. Revenue was up 309.8% from 2024-06-30 to 2025-06-30. PLUR currently screens at market cap $24.3M.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
PLUR currently screens at market cap $24.3M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the PLUR and REGN stock pages for the full models.
Not investment advice.